Management of Inotrope‑Resistant Shock

Initial Assessment and Optimization

• Confirm that adequate fluid resuscitation has been achieved before initiating vasopressors or inotropes. 1, 2
• Exclude mechanical causes that can mimic refractory shock (e.g., pericardial effusion, pneumothorax, intra‑abdominal pressure > 12 mmHg). 3, 4, 5
• Titrate dobutamine up to 20 µg/kg/min before labeling a patient as “inotrope‑resistant.” 1, 6
• Achieve a target mean arterial pressure (MAP) of ≥ 65 mmHg with vasopressors before adding inotropes. 1, 2, 6, 7

First‑Line Vasopressor Therapy

• Norepinephrine is the recommended first‑choice vasopressor and should be optimized before any additional agents are added. 2, 6, 8, 9
• If persistent hypoperfusion remains despite adequate MAP and fluid resuscitation, add dobutamine (up to 20 µg/kg/min). 1, 6, 8

Second‑Line (Catecholamine‑Sparing) Vasopressors

• Add vasopressin at 0.03 U/min to raise MAP or to allow reduction of norepinephrine dose when norepinephrine alone is insufficient. 2, 6, 10, 7
• Epinephrine may be added to, or substituted for, norepinephrine when an additional pressor is required. 2, 6, 10, 8
• Doses of vasopressin > 0.03–0.04 U/min should be reserved for salvage therapy only. 2, 10, 7

Corticosteroid Therapy

• Initiate hydrocortisone 200 mg/day when adequate fluid resuscitation and vasopressor therapy fail to restore hemodynamic stability. 1, 6, 8
• Hydrocortisone is especially indicated in patients at risk for absolute adrenal insufficiency. 3, 4, 5
• Taper hydrocortisone once vasopressor support is no longer required. 1

Salvage Vasopressor Options

• Phenylephrine may be used as a salvage agent, but it is generally not recommended except in specific clinical scenarios. 2, 10, 7

Advanced Hemodynamic Monitoring

• Consider pulmonary artery catheterization, PICCO, or FATD catheterization to guide fluid, inotrope, vasopressor, and vasodilator therapy. 3, 4, 5
• Doppler ultrasound can be employed to assess cardiac output and direct therapeutic adjustments. 3, 4, 5
• Target a cardiac index of 3.3–6.0 L/min/m² when using advanced monitoring. 3, 4, 5

Mechanical Circulatory Support

• Extracorporeal membrane oxygenation (ECMO) should be considered for refractory shock unresponsive to maximal medical therapy. 3, 4, 5
• Selection for ECMO must take into account patient age, comorbidities, and neurological status. 11

Critical Caveats and Pitfalls

• Avoid dopamine because it is associated with higher mortality and arrhythmias compared with norepinephrine; reserve its use for highly selected patients with low tachyarrhythmia risk and bradycardia. 2, 10, 8, 7
• Dobutamine and epinephrine carry a significant risk of tachyarrhythmias, which may worsen outcomes. 2, 10
• Titrate therapy to perfusion endpoints beyond blood pressure alone—monitor lactate, skin perfusion, mental status, and urine output. 10, 7
• Aggressively wean vasopressors while continuing appropriate fluid resuscitation. 10, 7

Phenotype‑Specific Considerations

• Cold shock (low cardiac output): Prioritize epinephrine titration and consider adding vasodilators (e.g., nitrosovasodilators, milrinone) if central venous oxygen saturation remains < 70 % despite adequate hemoglobin. 3, 4, 5
• Warm shock (high cardiac output, low systemic vascular resistance): Norepinephrine remains the preferred agent; consider vasopressin, terlipressin, or angiotensin‑converting enzyme inhibition if hypotension persists. 3, 4, 5, 9

Vasopressor and Inotrope Selection in Shock

General Principles

• Norepinephrine is the first‑line vasopressor for all shock states, with a target mean arterial pressure (MAP) of ≥ 65 mmHg. Strong evidence shows it reduces mortality and arrhythmias compared with dopamine. [12][13]14
• Adequate fluid resuscitation should precede vasopressor use (≥ 30 mL/kg crystalloid in septic shock). [12][13]
• Insert an arterial catheter early to enable continuous blood‑pressure monitoring. [12][13]

Septic Shock Management

First‑Line Vasopressor

• Start norepinephrine and titrate to MAP ≥ 65 mmHg. Recommended by the Intensive Care Medicine guidelines. [12][13]14

Second‑Line Add‑On Vasopressors

• Add vasopressin (fixed 0.03 U/min) when norepinephrine doses exceed ≈ 15 µg/min or MAP remains inadequate. [12][13]
• Reserve vasopressin doses > 0.03–0.04 U/min for salvage therapy only because of ischemia risk. [12][13]
• If additional support is needed, epinephrine (0.05–0.5 µg/kg/min) may be used as an alternative second‑line agent. [12][13]14

Inotrope for Persistent Hypoperfusion

• Add dobutamine (up to 20 µg/kg/min) when tissue hypoperfusion persists despite adequate MAP and fluid resuscitation. Indicated when lactate remains elevated, urine output falls, mental status deteriorates, or skin perfusion is poor. Decreased urine output is a key marker. [12][13][15][16]

Agents to Avoid

• Dopamine should not be used except in highly selected bradycardic patients; low‑dose dopamine for renal protection is strongly discouraged. [12][13][14][15] – Strong recommendation.
• Phenylephrine is reserved for salvage situations (e.g., norepinephrine‑induced arrhythmias, high‑output hypotension). 12

Cardiogenic Shock Management

• In the “cold” (low‑output) phenotype, norepinephrine remains the first‑line agent for MAP support and is associated with lower mortality than dopamine. 14

Refractory Shock

• When adequate fluids and vasopressors fail, initiate hydrocortisone 200 mg/day (continuous infusion) to address possible absolute adrenal insufficiency. 15

Safety and Pitfalls

• Dopamine increases mortality and arrhythmia risk compared with norepinephrine; limit its use to bradycardic patients with low tachyarrhythmia risk. [14][12]13
• Positive‑chronotropic agents (dopamine, levosimendan, epinephrine) may raise mortality risk, reinforcing norepinephrine as the preferred first‑line vasopressor. 14
• Avoid excessive vasoconstriction that impairs microcirculatory flow; titrate vasopressors to perfusion endpoints (lactate clearance, urine output, mental status) rather than blood pressure alone. 16

Dosing Summary